Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients

As novel biomarkers for gastroenteropancreatic neuroendocrine tumors (GEPNET) are in demand, we aimed to validate the clinical value of the NETest in Japanese patients. Between 2021 and 2023, blood and clinical data were collected from patients with GEPNET. Among 35 patients (median age: 59 [49–66]...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Hao Zhang, Takahiro Tsuchikawa, Satoshi Takeuchi, Kenji Hirata, Kimitaka Tanaka, Aya Matsui, Yoshitsugu Nakanishi, Toshimichi Asano, Takehiro Noji, Toru Nakamura, Shintaro Takeuchi, Masataka Wada, Satoshi Hirano
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	The Japan Endocrine Society 2024-09-01
سلاسل:	Endocrine Journal
الموضوعات:	gastroenteropancreatic neuroendocrine tumor netest japanese population application value peptide receptor radionuclide therapy
الوصول للمادة أونلاين:	https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0090/_html/-char/en
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!